Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.
References
1.
Wise J. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study. BMJ. :n61.
2.
Marin GH. Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discoveries & Therapeutics. 2020;14(2):105–6.
3.
Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(3):211–2.
4.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653–9.
5.
Li Y, Shi K, Qi F, Yu Z, Chen C, Pan J, et al. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. International Journal of Infectious Diseases. 2021;103:507–13.
6.
Plasma Therapy to Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine. 2021;384(25).
7.
Chhikara BS, Rathi B, Singh J, Poonam F. Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chem Biol Let. 2020;7:63–72.
8.
Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720.
9.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020;178:104787.
10.
Sharma A, Tiwari V, Sowdhamini R. Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products. Journal of Biosciences. 2020;45(1).
11.
Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Annals of Oncology. 2020;31(7):961–4.
12.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020;117(20):10970–5.
13.
Lima de Oliveira MD, Teixeira de Oliveira KM. Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs.
14.
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences. 2020;248:117477.
15.
Ziaie S, Koucheck M, Miri M. Review of therapeutic agents for the treatment of COVID-19. J Cel Mol Anesth. 2020;5:32–6.
16.
Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics. 2020;16(6):1232–8.
17.
Schmid-Wendtner MH, Korting HC. Penciclovir Cream – Improved Topical Treatment for Herpes simplex Infections. Skin Pharmacology and Physiology. 2004;17(5):214–8.
18.
Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects. PLoS Medicine. 3(9):e343.
19.
Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. The Lancet Respiratory Medicine. 2020;8(12):1170–2.
20.
Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384(8):693–704.
21.
Zheng F, Liao C, Fan Q hong, Chen H bo, Zhao X gong, Xie Z guo, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Current Medical Science. 2020;40(2):275–80.
22.
Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19. Pediatric Infectious Disease Journal. 2020;39(5):355–68.
23.
Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of <scp>SARS‐CoV</scp>‐2 during an outbreak in Iran: Comparison with <scp>SARS</scp> and <scp>MERS</scp>. Reviews in Medical Virology. 2020;30(3).
24.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473–5.
25.
Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney International. 2020;97(6):1076–82.
26.
Lernia V. Antipsoriatic treatments during COVID-19 outbreak. 2020.
27.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics. 2020;14(1):58–60.
28.
Kow CS, Hasan SS. Use of low-molecular-weight heparin in COVID-19 patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2020;8(5):900–1.
29.
Baccellieri D, Bertoglio L, Apruzzi L, Ardita V, D’Angelo A, Bossi M, et al. Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. Phlebology: The Journal of Venous Disease. 2021;36(5):375–83.
30.
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? International Journal of Antimicrobial Agents. 2020;55(4):105944.
31.
Razzaque MS. COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance? The Tohoku Journal of Experimental Medicine. 2020;251(3):175–81.
32.
S.J W. COVID-19 might be fought by 2 doses of Vitamin D (200,000-300,000 IU each)-Feb 2020. Europ J Biomed PharmSci. 2020;7:432–8.
33.
Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Critical Care. 2020;24(1).
34.
Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. ecancermedicalscience. 14.
Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World Journal of Pediatrics. 2020;16(3):271–4.
37.
A Trial of Lopinavir–Ritonavir in Covid-19. New England Journal of Medicine. 2020;382(21):e68.
38.
Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sciences. 2020;378:118205.
39.
Lee VS, Chong WL, Sukumaran SD, Nimmanpipug P, Letchumanan V, Goh BH, et al. Computational screening and identifying binding interaction of anti-viral and anti-malarial drugs: Toward the potential cure for SARS-CoV-2. Progress in Drug Discovery & Biomedical Science. 3(1).
40.
Ye X, Luo Y, Xia S. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390–6.
41.
Rismanbaf A. Potential Treatments for COVID-19: A Narrative Literature Review. Arch Acad Emerg Med. 2020;21;8(1:29.
42.
Kliger Y, Levanon EY. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiology. 3(1).
43.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein.
44.
Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. Journal of Clinical Investigation. 2017;127(4):1338–52.
45.
Abduljalil JM, Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New Microbes and New Infections. 2020;35:100672.
46.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020;55(3):105924.
47.
MOHSENI AFSHAR Z, BABAZADEH A, ALIZADEH KHATIR A, MOHAMMADNIA-AFROUZI M, JAVANIAN M, VASIGALA VR, et al. Neurological manifestations in COVID-19: an overview. Minerva Respiratory Medicine. 2021;60(2).
48.
Javanian M, Masrour-roudsari J, Bayani M, Ebrahimpour S. Coronavirus disease 2019 (COVID-19): What we need to know. Caspian J Intern Med. 2020;11(2):235–6.
49.
Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. Journal of Microbiology, Immunology and Infection. 2020;53(3):365–7.
50.
Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)—An emerging global health threat. Journal of Infection and Public Health. 2020;13(4):644–6.
51.
Z MA, S E, M J. Vital role of chest CT in diagnosis of coronavirus disease 2019 (COVID-19. Caspian J Intern Med. 2020;11:244–9.
52.
Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. L’Encéphale. 2020;46(3):169–72.
53.
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus–Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens: Figure 1. Clinical Infectious Diseases. 2015;61(6):974–7.
54.
Åkerström S, Gunalan V, Keng CT, Tan YJ, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1–9.
55.
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection. 2020;81(1):e21–3.
56.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020;81(1):e1–5.
57.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.
58.
Panati K, Narala VR. COVID-19 Outbreak: an Update on Therapeutic Options. SN Comprehensive Clinical Medicine. 2020;2(4):379–80.
59.
Remdesivir for the Treatment of Covid-19 — Preliminary Report. New England Journal of Medicine. 2020;383(10):992–4.
60.
Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MohdI, Patel SK, et al. SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review.
61.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. 2020;19(3):149–50.
62.
Shafiee S, Davaranb S. A mini-review on the current COVID-19 treatments. Clinical Trials. 21(25).
63.
Ayerbe L, Risco-Risco C, Núñez-Gil I, Perez-Piñar M, Ayis S. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? The Lancet Rheumatology. 2021;3(3):e172.
64.
GALLUS S, CLAVENNA A, LUGO A. Does hydroxychloroquine reduce mortality for COVID-19? European Journal of Internal Medicine. 2020;82:21–2.
65.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology. 2020;92(5):479–90.
66.
Zhang Y pei, Cui Q yan, Zhang T mei, Yi Y, Nie J jie, Xie G hui, et al. Chloroquine pretreatment attenuates ischemia-reperfusion injury in the brain of ob/ob diabetic mice as well as wildtype mice. Brain Research. 2020;1726:146518.
67.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269–71.
68.
Rios P, Radhakrishnan A, Antony J, Thomas S, Muller M, Straus SE, et al. Effectiveness and safety of antiviral or antibody treatments for coronavirus.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
